Telix Pharmaceuticals has entered an agreement to acquire Canadian diagnostic imaging isotopes company ARTMS for $82 million.
Under the agreement, Telix will take on ARTMS’ cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultrapure rare metals such as zinc-68, which is irradiated to produce gallium-68. The companies have been collaborating since 2020 to develop higher curie-scale production of Illuccix, a PET radiotracer injection kit used for prostate cancer imaging.
ARTMS is based in Burnaby, British Columbia, and is a privately held spin-off company of TRIUMF, Canada's particle accelerator center.
